Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 intravesical MK-3120 for high-risk non-muscle invasive bladder cancer
MOH_2025-11-11_015456Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MK-3120 in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Merck & Co. Primary endpoint: Safety and tolerability of intravesical MK-3120 monotherapy. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
MK-3120
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2025-11-11_015456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-11_015456.